February 9, 2007 – Sanofi-Aventis lost a patent battle in California over its $2.5 billion anti-clotting drug, Lovenox; Gilead and Achillion will discontinue development of GS 9132 for hepatitis C in favor of a similar drug, which delays their timelines; Neurobiological Technologies updated its progress with stroke drug Viprinex; Merck released data from a long running trial of its remaining COX-2 drug, Arcoxia; QLT and Sanofi-Aventis will pay $157.5 million to settle a patent case for Eligard, a hormonal treatment for prostate cancer; and Optimer priced its IPO at $7 and moved up to $8.50. The Centient Biotech 200™ fell 24 points to 4051, a loss of .58%. More details...
